352 related articles for article (PubMed ID: 19738431)
1. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
[TBL] [Abstract][Full Text] [Related]
2. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
[TBL] [Abstract][Full Text] [Related]
3. Calcium-dependent potassium channels as a target protein for modulation of the blood-brain tumor barrier.
Ningaraj NS; Rao M; Black KL
Drug News Perspect; 2003 Jun; 16(5):291-8. PubMed ID: 12942160
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.
Liu HL; Huang CY; Chen JY; Wang HY; Chen PY; Wei KC
PLoS One; 2014; 9(12):e114311. PubMed ID: 25490097
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
Hu J; Ljubimova JY; Inoue S; Konda B; Patil R; Ding H; Espinoza A; Wawrowsky KA; Patil C; Ljubimov AV; Black KL
PLoS One; 2010 Apr; 5(4):e10108. PubMed ID: 20419092
[TBL] [Abstract][Full Text] [Related]
6. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
[TBL] [Abstract][Full Text] [Related]
7. Adenosine 5'-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model.
Ningaraj NS; Rao MK; Black KL
Cancer Res; 2003 Dec; 63(24):8899-911. PubMed ID: 14695207
[TBL] [Abstract][Full Text] [Related]
8. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels.
Ningaraj NS; Rao M; Hashizume K; Asotra K; Black KL
J Pharmacol Exp Ther; 2002 Jun; 301(3):838-51. PubMed ID: 12023511
[TBL] [Abstract][Full Text] [Related]
9. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
10. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
[TBL] [Abstract][Full Text] [Related]
11. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Saito R; Bringas JR; Panner A; Tamas M; Pieper RO; Berger MS; Bankiewicz KS
Cancer Res; 2004 Oct; 64(19):6858-62. PubMed ID: 15466173
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Anai S; Hide T; Takezaki T; Kuroda J; Shinojima N; Makino K; Nakamura H; Yano S; Kuratsu J
Cancer Sci; 2014 May; 105(5):583-91. PubMed ID: 24673719
[TBL] [Abstract][Full Text] [Related]
13. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Fiveash JB; Gillespie GY; Oliver PG; Zhou T; Belenky ML; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):507-16. PubMed ID: 18474311
[TBL] [Abstract][Full Text] [Related]
15. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Lin CJ; Lee CC; Shih YL; Lin TY; Wang SH; Lin YF; Shih CM
Free Radic Biol Med; 2012 Jan; 52(2):377-91. PubMed ID: 22094224
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy.
Kato Y; Holm DA; Okollie B; Artemov D
Neuro Oncol; 2010 Jan; 12(1):71-9. PubMed ID: 20150369
[TBL] [Abstract][Full Text] [Related]
18. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Brem S; Tyler B; Li K; Pradilla G; Legnani F; Caplan J; Brem H
Cancer Chemother Pharmacol; 2007 Oct; 60(5):643-50. PubMed ID: 17256133
[TBL] [Abstract][Full Text] [Related]
19. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
20. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Grossman R; Rudek MA; Brastianos H; Zadnik P; Brem H; Tyler B; Blakeley JO
Cancer Chemother Pharmacol; 2012 Jul; 70(1):129-39. PubMed ID: 22644796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
